BlackRock’s Tonix Pharmaceuticals TNXP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.8M | Buy |
1,398,041
+429,864
| +44% | +$5.55M | ﹤0.01% | 3335 |
|
|
2026
Q1 | $13.3M | Buy |
968,177
+83,296
| +9% | +$1.28M | ﹤0.01% | 3319 |
|
|
2025
Q4 | $13.8M | Buy |
884,881
+203,351
| +30% | +$3.75M | ﹤0.01% | 3297 |
|
|
2025
Q3 | $16.5M | Buy |
681,530
+261,082
| +62% | +$9.69M | ﹤0.01% | 3203 |
|
|
2025
Q2 | $15.1M | Buy |
420,448
+350,868
| +504% | +$9.19M | ﹤0.01% | 3175 |
|
|
2025
Q1 | $1.24M | Buy |
69,580
+10,611
| +18% | +$215K | ﹤0.01% | 4131 |
|
|
2024
Q4 | $1.94M | Buy |
58,969
+58,961
| +737,013% | +$1.23M | ﹤0.01% | 4042 |
|
|
2024
Q3 | $117 | Sell |
8
-5
| -38% | -$201 | ﹤0.01% | 5185 |
|
|
2024
Q2 | $885 | Hold |
13
| – | – | ﹤0.01% | 5208 |
|
|
2024
Q1 | $7.59K | Hold |
13
| – | – | ﹤0.01% | 5110 |
|
|
2023
Q4 | $16.9K | Sell |
13
-2
| -13% | -$3.22K | ﹤0.01% | 5102 |
|
|
2023
Q3 | $26.4K | Hold |
15
| – | – | ﹤0.01% | 5105 |
|
|
2023
Q2 | $76.4K | Hold |
15
| – | – | ﹤0.01% | 4993 |
|
|
2023
Q1 | $178K | Hold |
15
| – | – | ﹤0.01% | 4810 |
|
|
2022
Q4 | $118K | Hold |
15
| – | – | ﹤0.01% | 4990 |
|
|
2022
Q3 | $165K | Sell |
15
-2
| -12% | -$49.1K | ﹤0.01% | 5029 |
|
|
2022
Q2 | $541K | Sell |
17
-37
| -69% | -$2.73M | ﹤0.01% | 4751 |
|
|
2022
Q1 | $7.92M | Buy |
54
+6
| +13% | +$918K | ﹤0.01% | 3711 |
|
|
2021
Q4 | $11M | Buy |
48
+5
| +12% | +$1.59M | ﹤0.01% | 3621 |
|
|
2021
Q3 | $16.4M | Buy |
43
+2
| +5% | +$974K | ﹤0.01% | 3414 |
|
|
2021
Q2 | $29.4M | Buy |
41
+29
| +242% | +$21.3M | ﹤0.01% | 3068 |
|
|
2021
Q1 | $9.73M | Buy |
12
+10
| +500% | +$7.65M | ﹤0.01% | 3590 |
|
|
2020
Q4 | $993K | Hold |
2
| – | – | ﹤0.01% | 4215 |
|
|
2020
Q3 | $1.24M | Buy |
+2
| New | +$1.21M | ﹤0.01% | 4053 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 5129 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 5079 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 5070 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 5078 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 4987 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 4894 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 4917 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 4860 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 4657 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 4409 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 4378 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 4364 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 4408 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 4411 |
|
Other funds holding TNXP
JHC
II
BlackRock's TNXP Position: Q2 2026 in Review
BlackRock increased its Tonix Pharmaceuticals (TNXP) stake by 44% in Q2 2026, buying an estimated $5.55M and bringing the position to 1,398,041 shares worth $17.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3335.
BlackRock first reported a position in TNXP in Q3 2020 and has held it in 24 quarters since. The position peaked at $29.4M in Q2 2021. 103 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.
- BlackRock held 1,398,041 shares of Tonix Pharmaceuticals worth $17.8M as of Q2 2026.
- BlackRock bought 429,864 Tonix Pharmaceuticals shares in Q2 2026, an estimated $5.55M.
- Tonix Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3335 holding.
- BlackRock first reported a position in Tonix Pharmaceuticals in Q3 2020 and has held it in 24 quarters since.
- BlackRock's Tonix Pharmaceuticals position peaked at $29.4M in Q2 2021.
- 103 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.